Published in Eur J Clin Pharmacol on August 04, 2007
Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother (2008) 1.08
Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol (2008) 0.98
Mycoses in the elderly. Eur J Clin Microbiol Infect Dis (2009) 0.89
Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. Br J Clin Pharmacol (2010) 0.88
Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach. AAPS J (2013) 0.84
In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J (2013) 0.82
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol (2012) 0.81
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol (2011) 0.79
Model-based meta-analysis of the effects of non-selective and α1-selective GABAA receptor agonists in healthy volunteers. Eur J Clin Pharmacol (2015) 0.78
Azole interactions with multidrug therapy in pediatric oncology. Eur J Clin Pharmacol (2012) 0.76
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Eur J Clin Pharmacol (2016) 0.76
What is the true risk of a pharmacokinetic drug-drug interaction? Eur J Clin Pharmacol (2007) 0.75
Respiratory depression related to multiple drug-drug interactions precipitated by a fluconazole loading dose in a patient treated with oxycodone. Eur J Clin Pharmacol (2017) 0.75
Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. Eur J Clin Pharmacol (2011) 0.75
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem (1994) 3.75
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos (2003) 2.91
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol (2001) 2.38
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther (2002) 2.15
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol (2003) 1.82
Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother (2003) 1.77
Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br Med J (1970) 1.71
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther (2005) 1.53
A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal (1998) 1.53
Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull (2005) 1.42
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg (1996) 1.31
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Pencil and paper tests--sensitivity to psychotropic drugs. Br J Clin Pharmacol (1984) 1.26
Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol (1994) 1.22
Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther (1989) 1.17
Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther (1992) 1.11
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos (1996) 1.06
Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther (1995) 1.01
Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther (1999) 0.99
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther (2006) 0.98
Elevation of steady-state diazepam levels by cimetidine. Clin Pharmacol Ther (1981) 0.90
Determination of fluconazole in human serum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther Drug Monit (1992) 0.89
No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther (2000) 0.89
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther (1999) 0.89
Fluconazole: a potent inhibitor of cytochrome P-450-dependent drug-metabolism in mice and humans in vivo. Comparative study with ketoconazole. Chem Pharm Bull (Tokyo) (1992) 0.86
Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos (1997) 0.86
Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol (1996) 0.85
Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth Analg (1983) 0.82
Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. Antimicrob Agents Chemother (2006) 0.82
The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg (1998) 0.81
Clinical importance of the interaction of diazepam and cimetidine. N Engl J Med (1984) 0.79
The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam Clin Pharmacol (1996) 0.79
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther (2006) 0.78
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther (1994) 0.78
Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacol Toxicol (1996) 0.78
Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol (1996) 0.77
Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos (1999) 0.77
Formation of active metabolites of psychotropic drugs. An updated review of their significance. Clin Pharmacokinet (1990) 0.76
Pharmacokinetic and pharmacodynamic interaction study of diazepam and metoprolol. Eur J Clin Pharmacol (1984) 0.75
Determination of diazepam and nordazepam in milk and plasma in the presence of oxazepam and temazepam. J Chromatogr (1991) 0.75
Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet (2003) 3.37
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther (2006) 3.09
Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Ther Drug Monit (2004) 2.84
SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev (2011) 2.08
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther (2002) 2.01
Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol (2005) 1.96
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics (2004) 1.87
Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther (2005) 1.79
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther (2005) 1.74
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther (2004) 1.68
Deeper chest compression - more complications for cardiac arrest patients? Resuscitation (2013) 1.66
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther (2004) 1.62
Comparison of endogenous 4β-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos (2013) 1.59
Medical emergency team activation: performance of conventional dichotomised criteria versus national early warning score. Acta Anaesthesiol Scand (2014) 1.54
Biodiversity, distributions and adaptations of Arctic species in the context of environmental change. Ambio (2004) 1.53
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics (2008) 1.52
Out-of-hospital administration of activated charcoal by emergency medical services. Ann Emerg Med (2005) 1.52
Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther (2004) 1.49
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol (2008) 1.48
Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 1.47
Feasibility and cardiac safety of inhaled xenon in combination with therapeutic hypothermia following out-of-hospital cardiac arrest. Crit Care Med (2013) 1.45
Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet (2011) 1.42
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos (2002) 1.40
Blood pressure during resuscitation in man--the effect of pause during rhythm analysis revisited. Resuscitation (2011) 1.38
Transfer of proinflammatory cytokines across term placenta. Obstet Gynecol (2005) 1.38
Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther (2002) 1.32
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther (2006) 1.30
Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther (2003) 1.25
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol (2011) 1.24
Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther (2005) 1.22
4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol (2008) 1.22
SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol (2009) 1.21
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther (2003) 1.21
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol (2002) 1.20
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One (2013) 1.17
Citalopram in pregnancy and lactation. Clin Pharmacol Ther (2002) 1.17
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem Biophys Res Commun (2005) 1.15
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos (2002) 1.14
Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther (2003) 1.14
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol (2007) 1.13
Prescription drugs during pregnancy and lactation--a Finnish register-based study. Eur J Clin Pharmacol (2003) 1.12
Bioavailability of dexmedetomidine after intranasal administration. Eur J Clin Pharmacol (2011) 1.12
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol (2006) 1.11
The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther (2003) 1.09
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol (2006) 1.09
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther (2003) 1.08
Responses to projected changes in climate and UV-B at the species level. Ambio (2004) 1.08
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. Eur J Clin Pharmacol (2008) 1.08
Validation of indirect calorimetry for measurement of energy expenditure in healthy volunteers undergoing pressure controlled non-invasive ventilation support. J Clin Monit Comput (2011) 1.08
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol (2003) 1.08
Infections and possible vaccine-drug interactions. Eur J Clin Pharmacol (2014) 1.07
Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther (2005) 1.07
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics (2009) 1.07
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics (2006) 1.06
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur J Clin Pharmacol (2006) 1.05
Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol (2003) 1.05
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol (2005) 1.04
Impacts of extreme winter warming events on plant physiology in a sub-Arctic heath community. Physiol Plant (2010) 1.04
Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patients. Crit Care (2011) 1.04
Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol (2003) 1.03
Prescription of hazardous drugs during pregnancy. Drug Saf (2004) 1.02
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos (2007) 1.02
Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy. Br J Clin Pharmacol (2008) 1.01
Methylprednisolone in neonatal cardiac surgery: reduced inflammation without improved clinical outcome. Ann Thorac Surg (2013) 1.01
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther (2004) 1.00
The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med (2009) 1.00
Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J (2009) 1.00
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol (2004) 0.99
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
Voriconazole drastically increases exposure to oral oxycodone. Eur J Clin Pharmacol (2008) 0.98
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther (2006) 0.98
Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups. Drugs Aging (2011) 0.98
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther (2004) 0.98
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther (2005) 0.97
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol (2008) 0.97
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci (2012) 0.97
Intravenous lipid emulsion sequesters amiodarone in plasma and eliminates its hypotensive action in pigs. Ann Emerg Med (2010) 0.97
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther (2003) 0.96
Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev (2011) 0.96
Intravenous lipid emulsion only minimally influences bupivacaine and mepivacaine distribution in plasma and does not enhance recovery from intoxication in pigs. Anesth Analg (2011) 0.96
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol (2006) 0.96
Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther (2004) 0.96
Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology (2009) 0.96
Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol (2006) 0.95
Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol (2007) 0.94
Diclofenac pharmacokinetic meta-analysis and dose recommendations for surgical pain in children aged 1-12 years. Paediatr Anaesth (2011) 0.94
Acetaminophen improves analgesia but does not reduce opioid requirement after major spine surgery in children and adolescents. Spine (Phila Pa 1976) (2012) 0.94
Quality controlled manual chest compressions and cerebral oxygenation during in-hospital cardiac arrest. Resuscitation (2011) 0.94
Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol (2007) 0.93
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenet Genomics (2008) 0.93
MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol (2009) 0.93